Related Experiment Video
Updated: Aug 6, 2026
Autologous Blood Injection to Model Spontaneous Intracerebral Hemorrhage in Mice
Published on: August 24, 2011
SC79 exerts neuroprotective effects in the model of experimental intracerebral hemorrhage
Xuehan Zhuang1, Min Fang2, Bo Feng3
1School of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, City of Yangzhou, Province of Jiangsu, China.
Insights
SC79, an AKT activator, shows promise for treating intracerebral hemorrhage (ICH). It reduces brain inflammation, oxidative stress, and neuronal death, improving recovery in ICH models.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Intracerebral hemorrhage (ICH) is a severe stroke subtype with limited treatment options.
- The AKT signaling pathway plays a critical role in cellular responses to stroke.
Purpose of the Study:
- To investigate the therapeutic potential of SC79, an AKT activator, in intracerebral hemorrhage (ICH).
- To explore the underlying mechanisms of SC79 action in both in vivo and in vitro ICH models.
Main Methods:
- Induced ICH in a rat model and used Hemin stimulation for in vitro microglial and neuronal cell models.
- Assessed neurological deficits, brain lesion, edema, inflammation, oxidative stress, and apoptosis using various tests and molecular techniques.
- Utilized transcriptome sequencing and bioinformatic analyses to elucidate SC79's mechanisms.
Main Results:
- SC79 administration improved functional recovery in ICH models.
- SC79 significantly suppressed neuroinflammation, oxidative stress, and neuronal apoptosis.
- Transcriptome analysis suggested SC79 acts through multiple pathways, including AKT activation.
Conclusions:
- SC79 demonstrates therapeutic potential for ICH by mitigating inflammatory injury, oxidative damage, and neuronal apoptosis.
- Activation of the AKT pathway is a key mechanism, but other pathways may also be involved.
- SC79 represents a promising therapeutic strategy for managing intracerebral hemorrhage.
Abstract:
Intracerebral hemorrhage (ICH) is the most devastating subtype of stroke, yet specific treatments with conclusive clinical benefit remain lacking. The protein kinase B (AKT) signaling pathway is essential to various cellular functions in stroke. The present study used SC79, a specific AKT activator previously validated in ischemic stroke models, to explore therapeutic approaches for ICH in both in vivo and in vitro models. Briefly, a rat model of ICH was induced with autologous blood, and in vitro ICH models were established by Hemin stimulation of the microglial cell line RM and the neuronal cell line HT22. Neurobehavioral tests, the gravimetric (wet/dry) method, and a range of molecular techniques were used to assess neurological deficits, brain lesion, brain edema, inflammation, oxidative stress, neuronal apoptosis, and the underlying mechanisms of SC79 treatment. The results showed that SC79 promoted functional recovery after ICH, mainly reflected by suppression of neuroinflammation and oxidative stress, attenuation of neuronal apoptosis, and improvement of neurological deficits. Transcriptome sequencing and bioinformatic analyses suggested that SC79 may act through multiple pathways in addition to AKT activation. Taken together, these findings indicate that SC79 attenuates inflammatory injury, oxidative damage, and neuronal apoptosis after ICH, at least in part through AKT activation, and may represent a promising therapeutic strategy for ICH.
